Guideline Summary for Management of Von Willebrand Disease

Diagnostic Classification

• Accurate subtyping using VWF antigen, VWF activity (ristocetin cofactor or GP1b binding), FVIII levels, and genetic testing directs therapy and avoids dangerous errors, especially the contraindication of DDAVP in Type 2B VWD. 1

Type 1 VWD (≈70‑80 % of cases)

First‑line Hemostatic Agent

• Desmopressin (DDAVP) 0.3 µg/kg diluted in 50 mL saline infused over 20–30 min is the initial treatment for Type 1 VWD. 2
• DDAVP raises endogenous VWF and FVIII concentrations 2–3‑fold, with peak levels at 30–60 min after infusion. 2
• Tachyphylaxis develops after three consecutive DDAVP doses; further bleeding should be managed with VWF/FVIII concentrates. 2

Second‑line Therapy

• When DDAVP response is inadequate or contraindicated, plasma‑derived or recombinant VWF/FVIII concentrates become the primary therapy. 1

Adjunctive Antifibrinolytic Therapy

• Adding tranexamic acid to DDAVP or VWF/FVIII concentrates improves hemostasis, achieving >90 % success when combined with DDAVP. 3

Type 2 VWD (Qualitative Defects)

General Management

• VWF/FVIII concentrates are the primary treatment for Type 2A, 2M, and 2N because of dysfunctional VWF protein. 1

Type 2N Specifics

• In patients with VWF and FVIII levels <50 IU/dL, therapeutic options include DDAVP, antifibrinolytics, and factor replacement. 4

DDAVP Use in Subtypes

• DDAVP may be effective in selected Type 2A and 2M patients after a documented trial response. 1

Type 2B (Gain‑of‑Function)

• DDAVP is absolutely contraindicated in Type 2B VWD due to risk of platelet clumping, consumption, and thrombocytopenia. 4
• VWF/FVIII concentrates are the sole appropriate replacement; platelet transfusion may be required if significant thrombocytopenia develops. 4

Type 3 VWD (Severe, Near‑Total Absence)

• Regular prophylactic infusion of VWF/FVIII concentrates is required to prevent spontaneous joint, muscle, and mucosal bleeding. 1
• DDAVP is ineffective because endogenous VWF stores are absent. 2
• Screen for allo‑antibodies against VWF; if inhibitors are present, bypassing agents (FEIBA or recombinant FVIIa) should be used under hematology guidance. 4

Perioperative Management

Major Surgery / Neuraxial Anesthesia

• Target VWF and FVIII levels ≥50 IU/dL peri‑operatively. 5
• For DDAVP‑responsive Type 1 patients, administer DDAVP 30–60 min before the procedure. 2
• For all other subtypes or DDAVP non‑responders, give VWF/FVIII concentrates to achieve the target levels. 1
• Add tranexamic acid as adjunctive therapy, especially for procedures involving mucosal surfaces. 2

Minor Surgery / Procedures

• DDAVP ± tranexamic acid provides adequate hemostasis for most Type 1 patients. 3
• For Type 2 (except 2B) and Type 3, use VWF/FVIII concentrates even for minor procedures. 1

Obstetric Management

• Maintain VWF and FVIII >50 IU/dL for 5–7 days postpartum by giving 40–60 IU/kg VWF‑containing concentrate at delivery and once daily thereafter. 4
• Neuraxial anesthesia during labor requires VWF and FVIII ≥50 IU/dL. 5
• Continue antifibrinolytics for at least 2 weeks postpartum to reduce the risk of postpartum hemorrhage. 4

Alternative Therapy When Concentrates Unavailable

• If VWF/FVIII concentrates are unavailable and DDAVP fails or is contraindicated, cryoprecipitate is indicated as a substitute. 6
• Cryoprecipitate contains VWF and fibrinogen but is less standardized than purified concentrates. 6

Monitoring and Follow‑Up

• All factor‑concentrate prescriptions should be directed by a hematologist. 4
• For surgical bleeding, monitor aPTT (prolonged with low FVIII), hemoglobin, hematocrit, fibrinogen, and platelet count. 2
• Viscoelastic testing can guide transfusion decisions but does not replace factor‑specific assays for VWF or FVIII activity. 2

Key Clinical Pitfalls

• Never administer DDAVP to patients with Type 2B VWD; it precipitates dangerous platelet aggregation and consumption. 4
• Do not exceed three consecutive DDAVP doses without switching to concentrates because of tachyphylaxis. 2
• Absence of a family history does not exclude VWD; de novo mutations and variable penetrance are common. 2
• Prophylactic DDAVP in individuals without documented VWD or platelet defects provides no benefit and should be avoided. 3

Perioperative Management and Clearance of Patients with von Willebrand Disease

Pre‑Operative Assessment

• Confirm VWD subtype using quantitative VWF antigen, VWF activity (ristocetin cofactor or GP1b binding), and FVIII levels to guide therapy selection. 7
• Obtain a detailed personal bleeding history, including responses to prior surgeries or hemostatic challenges, to stratify individual risk. 7
• Perform a DDAVP trial in patients with suspected Type 1 VWD when a prior response has not been documented, to determine suitability for DDAVP‑based therapy. 8
• Recognize that Type 2B VWD patients develop dangerous platelet clumping with DDAVP; accurate subtyping is therefore mandatory before any hemostatic intervention. 7

Perioperative Management by VWD Type

Type 1 VWD (≈70‑80 % of cases)

• Major surgery: Aim for peri‑operative VWF and FVIII activity ≥50 IU/dL. First‑line therapy is DDAVP 0.3 µg/kg IV infused over 20‑30 min, administered 30‑60 min before incision. DDAVP typically raises VWF/FVIII 2‑3‑fold with a peak at 30‑60 min. Switch to VWF/FVIII concentrates if the DDAVP response is inadequate or after three consecutive doses (to avoid tachyphylaxis). [9] [7] 8
• Minor surgery: DDAVP (with or without tranexamic acid) is usually sufficient to achieve hemostasis.

Type 2 VWD (Qualitative defects)

• Types 2A, 2M, 2N: Primary therapy is VWF/FVIII concentrate (plasma‑derived or recombinant) dosed to reach VWF and FVIII ≥50 IU/dL. In Type 2N with baseline levels <50 IU/dL, DDAVP, antifibrinolytics, or factor replacement may be considered. 7
• Type 2B (gain‑of‑function): DDAVP is absolutely contraindicated because it precipitates platelet aggregation and thrombocytopenia. Management relies exclusively on VWF/FVIII concentrates; platelet transfusion is added if severe thrombocytopenia occurs. 7

Type 3 VWD (Severe, near‑total deficiency)

• VWF/FVIII concentrates are mandatory for all procedures; DDAVP is ineffective due to the lack of endogenous VWF stores. 9

Target Levels and Monitoring

• For major surgery, maintain VWF and FVIII activity ≥50 IU/dL for 7‑14 days post‑operatively to prevent delayed bleeding. 9
• For neuraxial anesthesia, ensure VWF and FVIII ≥50 IU/dL before needle placement. 9
• Intra‑operative labs: aPTT may be prolonged with low FVIII but is not a reliable predictor of bleeding; monitor hemoglobin, hematocrit, fibrinogen, and platelet count. Viscoelastic testing can assist transfusion decisions but does not replace specific VWF/FVIII assays. [9] [8]

Dosing Guidance for VWF/FVIII Concentrates

• Loading dose: 40‑60 IU/kg of a VWF‑containing concentrate. 9
• Maintenance: Once‑daily dosing (or as clinically indicated) to keep target VWF/FVIII levels ≥50 IU/dL. 9
• All concentrate prescriptions must be directed by a hematologist experienced in VWD management. 9

Clearance Decision Algorithm

• Verify VWD subtype with laboratory testing. 7
• Review the patient’s bleeding history and prior surgical outcomes. 7
• For Type 1 patients without a documented DDAVP response, conduct a trial to assess suitability. 8
• Coordinate with hematology to confirm availability of appropriate factor concentrates and finalize dosing plans. 9
• Communicate the bleeding risk and monitoring protocol to the surgical team. 7
• Grant surgical clearance only after a comprehensive hemostatic plan is established and necessary products are on hand. 7